Immutep (NASDAQ:IMMP) Stock Price Passes Below Fifty Day Moving Average - Here's What Happened
Immutep (NASDAQ:IMMP) shares fell below their 50-day moving average of $0.18, trading as low as $0.80 before closing at $0.84 with a volume of 70,057 shares. The company has a current ratio of 18.25 and a debt-to-equity ratio of 0.01. Institutional investors have recently adjusted their stakes, with notable increases from firms like BNP Paribas and Virtu Financial. Immutep is a clinical-stage biotechnology company focused on developing LAG-3 immunotherapy for cancer and autoimmune diseases.
Shares of Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.18 and traded as low as $1.80. Immutep shares last traded at $1.84, with a volume of 70,057 shares traded.
Immutep Stock Up 0.5 %
- Why Did Immutep Ltd Stock Soar Recently?
The company's 50-day moving average price is $2.18 and its 200-day moving average price is $2.35. The company has a current ratio of 18.25, a quick ratio of 18.25 and a debt-to-equity ratio of 0.01.
Institutional Investors Weigh In On Immutep
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Immutep in the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets grew its holdings in Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company's stock worth $82,000 after purchasing an additional 4,700 shares during the period. XY Capital Ltd bought a new position in Immutep during the second quarter worth about $105,000. Virtu Financial LLC increased its position in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company's stock worth $105,000 after buying an additional 32,864 shares during the last quarter. Finally, Oracle Investment Management Inc. raised its stake in Immutep by 9.4% in the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company's stock valued at $1,316,000 after buying an additional 48,449 shares during the period. 2.32% of the stock is owned by institutional investors.
Immutep Company Profile
(Get Free Report)Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
- Five stocks we like better than Immutep
- How to Use the MarketBeat Excel Dividend Calculator
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Breakout Alert: Qualcomm Just Hit The Rally Button
- How to Invest in Insurance Companies: A Guide
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Urgent: This election is rigged (From Porter & Company) (Ad)
Should you invest $1,000 in Immutep right now?
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here